193 related articles for article (PubMed ID: 32403886)
1. [Clinicopathological analysis of 16 cases of pyrrolizidine alkaloids-associated hepatic sinusoidal obstruction syndrome].
Li YS; Bao J; Xu Y; Wang TL
Zhonghua Gan Zang Bing Za Zhi; 2020 Apr; 28(4):332-337. PubMed ID: 32403886
[No Abstract] [Full Text] [Related]
2. Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study.
Liu F; Rong X; Guo H; Xu D; Liu C; Meng L; Yang X; Guo T; Kan X; Song Y
BMC Gastroenterol; 2020 Feb; 20(1):30. PubMed ID: 32019495
[TBL] [Abstract][Full Text] [Related]
3. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.
Gao H; Ruan JQ; Chen J; Li N; Ke CQ; Ye Y; Lin G; Wang JY
Drug Des Devel Ther; 2015; 9():4861-8. PubMed ID: 26346783
[TBL] [Abstract][Full Text] [Related]
4. Histological evaluation of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: Correlation with Drum Tower Severity Scoring.
Li R; Li L; Cai Z; Chen J; Zhang H; Zhao S; Tu J; Sun C; Jin Y; Zhang M; Zhang F; Zhang W; Yin Q; Xu H; Han H; Li T; Zhuge Y; Xiao J
Dig Liver Dis; 2024 Jul; 56(7):1220-1228. PubMed ID: 38151450
[TBL] [Abstract][Full Text] [Related]
5. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.
Yang XQ; Ye J; Li X; Li Q; Song YH
World J Gastroenterol; 2019 Jul; 25(28):3753-3763. PubMed ID: 31391770
[TBL] [Abstract][Full Text] [Related]
6. Tusanqi and hepatic sinusoidal obstruction syndrome.
Wang JY; Gao H
J Dig Dis; 2014 Mar; 15(3):105-7. PubMed ID: 24528632
[TBL] [Abstract][Full Text] [Related]
7. Gynura Rhizoma containing pyrrolizidine alkaloids induces the hepatic sinusoidal obstruction syndrome in mice via upregulating fibrosis-related factors.
Zhang F; Zhou Y; Yang X; Xiong AZ; Wang ZT; Yang L
Acta Pharmacol Sin; 2019 Jun; 40(6):781-789. PubMed ID: 30367152
[TBL] [Abstract][Full Text] [Related]
8. Characterization of liver injury induced by a pyrrolizidine alkaloid in rats.
Chen X; Ma J; He Y; Xue J; Song Z; Xu Q; Lin G
Phytomedicine; 2021 Aug; 89():153595. PubMed ID: 34153877
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparin in the treatment of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: five case reports.
Jiang M; Wang L; Du X; Hao M; Gao P
J Int Med Res; 2020 Sep; 48(9):300060520961916. PubMed ID: 32993424
[TBL] [Abstract][Full Text] [Related]
10. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Zhuge Y; Liu Y; Xie W; Zou X; Xu J; Wang J;
J Gastroenterol Hepatol; 2019 Apr; 34(4):634-642. PubMed ID: 30669184
[TBL] [Abstract][Full Text] [Related]
11. Bear bile powder attenuates senecionine-induced hepatic sinusoidal obstruction syndrome in mice.
Jiang KY; Zhang Y; Ye XL; Xiong F; Chen Y; Jia XL; Zhang YX; Yang L; Xiong AZ; Wang ZT
Chin J Nat Med; 2022 Apr; 20(4):270-281. PubMed ID: 35487597
[TBL] [Abstract][Full Text] [Related]
12. Defibrotide improved the outcome of monocrotaline induced rat hepatic sinusoidal obstruction syndrome.
Liu Z; Liang S; Wei X; Du X; Zhang J
BMC Gastroenterol; 2022 Dec; 22(1):525. PubMed ID: 36526956
[TBL] [Abstract][Full Text] [Related]
13. A TMT-based shotgun proteomics uncovers overexpression of thrombospondin 1 as a contributor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Wang W; Chen Y; Yin Y; Wang X; Ye X; Jiang K; Zhang Y; Zhang J; Zhang W; Zhuge Y; Chen L; Peng C; Xiong A; Yang L; Wang Z
Arch Toxicol; 2022 Jul; 96(7):2003-2019. PubMed ID: 35357534
[TBL] [Abstract][Full Text] [Related]
14. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans.
Yang M; Ruan J; Gao H; Li N; Ma J; Xue J; Ye Y; Fu PP; Wang J; Lin G
Arch Toxicol; 2017 Dec; 91(12):3913-3925. PubMed ID: 28620673
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Toxification of 1,2-Unsaturated Pyrrolizidine Alkaloids Causes Human Hepatic Sinusoidal Obstruction Syndrome: The Update.
Teschke R; Vongdala N; Quan NV; Quy TN; Xuan TD
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638760
[TBL] [Abstract][Full Text] [Related]
16. Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Wang X; Zhang W; Zhang M; Zhang F; Xiao J; Yin Q; Han H; Li T; Lin G; Zhuge Y
Hepatol Int; 2022 Jun; 16(3):669-679. PubMed ID: 35023026
[TBL] [Abstract][Full Text] [Related]
17. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.
Gao H; Li N; Wang JY; Zhang SC; Lin G
J Dig Dis; 2012 Jan; 13(1):33-9. PubMed ID: 22188914
[TBL] [Abstract][Full Text] [Related]
18. Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Wu F; Yu J; Gan H; Zhang H; Tian D; Zheng D
Sci Rep; 2021 Nov; 11(1):21743. PubMed ID: 34741082
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Analysis of CT Images in Patients with Pyrrolizidine Alkaloid-Induced Sinusoidal Obstruction Syndrome.
Wang C; Wu X; Xie W; Ren X; Zhang W; Xu J
Sci Rep; 2019 Feb; 9(1):2179. PubMed ID: 30778132
[TBL] [Abstract][Full Text] [Related]
20. Expression of MMP-9 in hepatic sinusoidal obstruction syndrome induced by Gynura segetum.
Yu XZ; Ji T; Bai XL; Liang L; Wang LY; Chen W; Liang TB
J Zhejiang Univ Sci B; 2013 Jan; 14(1):68-75. PubMed ID: 23303633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]